sefulness and safety of vaccine for Mumps-Measles-Rubella in the treatment of wart(s) caused by viruses
Not Applicable
- Conditions
- Health Condition 1: null- Multiple viral warts
- Registration Number
- CTRI/2018/03/012515
- Lead Sponsor
- Medical College Kolkata
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Closed to Recruitment of Participants
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
i.Patients having clinically diagnosed wart(s).
ii.Patients who give their informed consent.
iii.Patients not having received any anti-wart treatment in the past 4 weeks
iv.Lack of viral diseases such as herpes and/or bacterial infections such as impetigo.
Exclusion Criteria
i.Pregnant and lactating women.
ii.Any evidence of immunosuppression (eg. HIV infection, organ transplantation, long term steroid use etc.).
iii.Any other systemic disease (eg. liver or kidney disorder).
iv.Presence of mucosal wart(s).
v.Presence of ulcerated or inflamed wart(s).
vi.Presence of wart(s) in face proper.
vii.Patients who participated in a clinical trial in the last three months.
viii.Patients not giving consent
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Reduction in the size and total number of lesions- <br/ ><br>a.Complete removal <br/ ><br>b.Partial clearance <br/ ><br>c.No response <br/ ><br>Timepoint: Baseline, 2, 4, 8, 12, 16, 20, 24, 28 weeks
- Secondary Outcome Measures
Name Time Method Serum for Liver Function Test, Urea, Creatinine, Hemoglobin, Total count, Differential Count, Erythrocyte Sedimentation Rate, Fasting blood sugarTimepoint: Screening visit, 4 weeks